Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Market Closed 03-21 16:00:00 EDT

3.88

+0.00

0.00%

盘后3.88

+0.000.00%

19:30 EDT

High3.92	Low3.78	Vol428.04K
Open3.82	D1 Closing3.88	Amplitude3.74%
Mkt Cap214.20M	Tradable Cap174.67M	Total Shares55.21M
T/O1.65M	T/O Rate0.95%	Tradable Shares45.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":3.88,"timestamp":1742587200000,"preClose":3.88,"halted":0,"volume":428036,"hourTrading":{"tag":"盘后","latestPrice":3.88,"preClose":3.88,"latestTime":"19:30 EDT","volume":37317,"amount":144788.710645,"timestamp":1742599835165},"delay":0,"floatShares":45018205,"shares":55206885,"eps":-1.13,"marketStatus":"Market Closed","change":0,"latestTime":"03-21 16:00:00 EDT","open":3.82,"high":3.92,"low":3.775,"amount":1648352.1683832,"amplitude":0.037371,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1742803200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":3.88,"preHourTrading":{"tag":"盘前","latestPrice":3.82,"preClose":3.88,"latestTime":"08:17 EDT","volume":20,"amount":76.39999999999999,"timestamp":1742559440059},"postHourTrading":{"tag":"盘后","latestPrice":3.88,"preClose":3.88,"latestTime":"19:30 EDT","volume":37317,"amount":144788.710645,"timestamp":1742599835165},"volumeRatio":1.3409834590687404,"impliedVol":1.5256,"impliedVolPercentile":0.828},"requestUrl":"/m/hq/s/VYGR","defaultTab":"news","newsList":[{"id":"2520564793","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Teleflex (TFX) and Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520564793","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520564793?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 14:30","pubTimestamp":1742193028,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report) and Voyager Therapeutics (VYGR –...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-teleflex-tfx-and-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-teleflex-tfx-and-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4588","BK4082","BK4137","BK4504","VYGR","TFX","HCSG"],"gpt_icon":0},{"id":"2520556199","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520556199","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520556199?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 14:21","pubTimestamp":1742192460,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), Labco...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-labcorp-holdings-lh-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-labcorp-holdings-lh-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR","LU0006061336.USD","LU1059921491.USD","HCSG","BK4588","BK4196","BK4585","ARQT","BK4137","BK4550","LH"],"gpt_icon":0},{"id":"2519548538","title":"Voyager Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2519548538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519548538?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 00:26","pubTimestamp":1741883160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 12:26 ET (16:26 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2519884939","title":"Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519884939","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519884939?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:28","pubTimestamp":1741861680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 06:28 ET (10:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2519881024","title":"Voyager Therapeutics: Strong Buy Rating Backed by Strategic Partnerships and Promising Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2519881024","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519881024?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:17","pubTimestamp":1741861039,"startTime":"0","endTime":"0","summary":"In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-buy-rating-backed-by-strategic-partnerships-and-promising-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-buy-rating-backed-by-strategic-partnerships-and-promising-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2518108072","title":"Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2518108072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518108072?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 11:35","pubTimestamp":1741750516,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on March 3. Phil Nadeau has given his Buy ratin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-financials-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strong-financials-and-promising-pipeline-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2518196705","title":"Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2518196705","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518196705?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 05:10","pubTimestamp":1741727404,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics  came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -68.57%. A quarter ago, it was expected that this gene therapy company would post a loss of $0.45 per share when it actually produced a loss of $0.16, delivering a surprise of 64.44%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Voyager Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.28 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 68.81%. This compares to year-ago revenues of $90.06 million. The company has topped consensus revenue estimates three times over the last four quarters.Voyager Therapeutics shares have lost about 26.5% since the beginning of the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-therapeutics-vygr-reports-q4-211004646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR"],"gpt_icon":0},{"id":"2518777695","title":"Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2518777695","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518777695?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 05:01","pubTimestamp":1741726911,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryVoyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 59 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nL8N3PU2H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2518077767","title":"Voyager Therapeutics: Q4 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2518077767","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518077767?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:25","pubTimestamp":1741724726,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass.  — LEXINGTON, Mass.  — Voyager Therapeutics Inc.  on Tuesday reported a loss of $34.5 million in its fourth quarter.On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 59 cents.The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 35 cents per share.The gene therapy company posted revenue of $6.3 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $20.1 million.For the year, the company reported a loss of $65 million, or $1.13 per share. Revenue was reported as $80 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-therapeutics-q4-earnings-snapshot-202526592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR"],"gpt_icon":0},{"id":"2518774369","title":"Voyager Therapeutics reports Q4 EPS (59c), consensus (35c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518774369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518774369?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:16","pubTimestamp":1741724185,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $$6.278M, consensus $16.58M.” Over the past year, Voyager has significantly advanced our two wholly-owned programs targeting tau...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q4-eps-59c-consensus-35c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q4-eps-59c-consensus-35c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2518077908","title":"Voyager Therapeutics Q4 2024 GAAP EPS $(0.59) Misses $(0.38) Estimate, Sales $6.278M Miss $16.577M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518077908","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518077908?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:02","pubTimestamp":1741723361,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.38) by 55.26 percent. This is a 147.2 percent decrease over earnings of $1.25 per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44262049/voyager-therapeutics-q4-2024-gaap-eps-0-59-misses-0-38-estimate-sales-6-278m-miss-16-577m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Voyager Therapeutics Q4 2024 GAAP EPS $(0.59) Misses $(0.38) Estimate, Sales $6.278M Miss $16.577M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2518779714","title":"Voyager Therapeutics Inc: Sees to Meet Planned Oper Expenses and Capex Needs Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2518779714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518779714?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:01","pubTimestamp":1741723261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nPLXA60D79:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2518719779","title":"Voyager Therapeutics Q4 Basic EPS USD -0.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2518719779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518719779?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:01","pubTimestamp":1741723261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nPLXA60D79:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2518779051","title":"Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518779051","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518779051?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:01","pubTimestamp":1741723260,"startTime":"0","endTime":"0","summary":"- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -. - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer’s patients expected H2 2026 -. LEXINGTON, Mass., March 11, 2025  -- Voyager Therapeutics, Inc. , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2024 financial and operating results.Runway extended into mid-2027 as VY9323 no longer advancing: Voyager previously announced that it is as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-reports-fourth-quarter-full-200100057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR"],"gpt_icon":0},{"id":"2517542463","title":"Voyager Therapeutics Inc  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2517542463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517542463?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 04:53","pubTimestamp":1741380798,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc  expected to post a loss of37cents a share - Earnings Preview Voyager Therapeutics Inc VYGR.OQ VYGR.O is expected to show a fall in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL5N3PQ256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2517100609","title":"Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), Senseonics Holdings (SENS) and Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517100609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517100609?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 18:20","pubTimestamp":1741342822,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Elanco Animal Health (ELAN – Research Report), Sen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-elanco-animal-health-elan-senseonics-holdings-sens-and-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-elanco-animal-health-elan-senseonics-holdings-sens-and-voyager-therapeutics-vygr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SENS","HCSG","BK4561","BK4139","ELAN","BK4137","BK4007","BK4082","VYGR"],"gpt_icon":0},{"id":"2516620748","title":"Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620748","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620748?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., March 04, 2025  -- Voyager Therapeutics, Inc. , a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.Voyager Therapeuticsis a registered trademark, and TRACER is a trademark, ofVoyager Therapeutics, Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-therapeutics-announces-fourth-quarter-120000456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2516657210","title":"Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516657210","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516657210?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 03:27","pubTimestamp":1741030053,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics  reported positive results Monday from the single ascending dose trial of its investigational antibody VY7523, developed to selectively inhibit the spread of pathological tau in Alzheimer's disease.Data from the trial demonstrated the safety, tolerability, and dose-proportional pharmacokinetics of single intravenous doses in 48 healthy volunteers, the company said.The drug was well tolerated across all six ascending dose cohorts, meeting the primary objective of the trial, with no serious adverse events, severe adverse events, or infusion reactions reported.Voyager said it has initiated a multiple ascending dose trial of the drug in patients with early Alzheimer's disease, which is expected to generate initial tau positron emission tomography  imaging data in H2 2026.Voyager shares were down nearly 3% in recent trading.Price: 3.97, Change: -0.11, Percent Change: -2.70","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PET","PET.AU","BK4192","BK7047","VYGR","BK4139"],"gpt_icon":0},{"id":"2516656973","title":"Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656973","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656973?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 00:45","pubTimestamp":1741020300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 11:45 ET (16:45 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2516870356","title":"Voyager Therapeutics Inc - Vy7523 Demonstrates Safety, Tolerability, and Dose-Proportional Pharmacokinetics in Sad Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516870356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516870356?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 20:08","pubTimestamp":1741003725,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0051},{"period":"1month","weight":-0.0977},{"period":"3month","weight":-0.3252},{"period":"6month","weight":-0.3792},{"period":"1year","weight":-0.5872},{"period":"ytd","weight":-0.3157}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0799},{"period":"3month","weight":-0.046},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.08},{"period":"ytd","weight":-0.0377}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.005473},{"month":2,"riseRate":0.5,"avgChangeRate":0.058533},{"month":3,"riseRate":0.5,"avgChangeRate":0.059796},{"month":4,"riseRate":0.444444,"avgChangeRate":0.015432},{"month":5,"riseRate":0.666667,"avgChangeRate":0.071442},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.003427},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.023998},{"month":8,"riseRate":0.555556,"avgChangeRate":-0.028879},{"month":9,"riseRate":0.111111,"avgChangeRate":0.036077},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.01151},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.073556},{"month":12,"riseRate":0.5,"avgChangeRate":-0.035937}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction